Publication:
Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.

Loading...
Thumbnail Image
Date
2016-01-01
Authors
LÜ, J
ZHANG, J
JIANG, C
DENG, Y
Özten, NUR
BOSLAND, MC
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue

Metrics

Search on Google Scholar

Abstract
The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of non-small cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify two major lessons from the outcomes of these trials: 1) The antioxidant hypothesis was tested in wrong subjects or patient populations. 2) The selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to re-vitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.
Description
Keywords
Citation
LÜ J., ZHANG J., JIANG C., DENG Y., Özten N., BOSLAND M., -Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.-, Nutrition and cancer, cilt.68, ss.1-17, 2016
Page Views

0

File Downloads

7

Sustainable Development Goals